PMID- 31373505
OWN - NLM
STAT- MEDLINE
DCOM- 20200914
LR  - 20200914
IS  - 1130-0108 (Print)
IS  - 1130-0108 (Linking)
VI  - 111
IP  - 10
DP  - 2019 Oct
TI  - The status of proton pump inhibitor use: a prescription survey of 45 hospitals in 
      China.
PG  - 738-743
LID - 10.17235/reed.2019.6155/2019 [doi]
AB  - BACKGROUND: proton pump inhibitors (PPI) have been widely used in the clinic but 
      inappropriate prescribing has also increased dramatically. OBJECTIVE: to describe 
      the prescribing patterns and assess the appropriateness of the prescribed PPI use 
      in 45 hospitals in China. MATERIALS AND METHODS: PPI prescriptions for 
      non-hospitalized patients were collected from hospitals in Beijing, Chengdu, 
      Guangzhou and Hangzhou of China over a 40-day period in 2016. These data were 
      analyzed using the prescription number, proportion and economic indicators 
      (defined daily dose system [DDD], defined daily cost [DDC] and drug utilization 
      index [DUI]). The evaluation criteria of PPI use was based on Martindale: The 
      Complete Drug Reference, New Materia Medica and drug instructions. RESULTS: in 
      total, 357,687 prescriptions using oral PPI and 38,216 prescriptions using 
      injectable PPI were assessed. The average age of PPI users was 53 years. The most 
      commonly used oral PPI was rabeprazole, while the most common injectable PPI was 
      pantoprazole. The DDD of oral rabeprazole and DDC of injectable rabeprazole were 
      the highest. Meanwhile, only the DUI values of oral rabeprazole, lansoprazole and 
      ilaprazole were less than 1.0. The clinical diagnosis of some users included well 
      identified risky comorbidities such as kidney disease (2.9%). Furthermore, 
      between 32.6% and 56.8% of the PPI prescriptions were used for inappropriate 
      indications. CONCLUSION: this survey demonstrated that PPI use was accompanied by 
      unapproved indications and excessive dosages. Comprehensive measures are urgently 
      needed to improve PPI use and reduce unnecessary drug costs.
FAU - Ying, Jie
AU  - Ying J
AD  - Sir Run Run Shaw Hospital.
FAU - Li, Liu-Cheng
AU  - Li LC
AD  - Sir Run Run Shaw Hospital.
FAU - Wu, Cui-Yun
AU  - Wu CY
AD  - Sir Run Run Shaw Hospital.
FAU - Yu, Zhen-Wei
AU  - Yu ZW
AD  - Sir Run Run Shaw Hospital.
FAU - Kan, Lian-Di
AU  - Kan LD
AD  - Department of Pharmacy, Sir Run Run Shaw Hospital, China.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PL  - Spain
TA  - Rev Esp Enferm Dig
JT  - Revista espanola de enfermedades digestivas
JID - 9007566
RN  - 0 (2-Pyridinylmethylsulfinylbenzimidazoles)
RN  - 0 (Proton Pump Inhibitors)
RN  - 0K5C5T2QPG (Lansoprazole)
RN  - 32828355LL (Rabeprazole)
RN  - 776Q6XX45J (ilaprazole)
RN  - D8TST4O562 (Pantoprazole)
RN  - N3PA6559FT (Esomeprazole)
SB  - IM
MH  - 2-Pyridinylmethylsulfinylbenzimidazoles/administration & dosage/therapeutic use
MH  - Adolescent
MH  - Adult
MH  - China
MH  - Comorbidity
MH  - Esomeprazole/administration & dosage/therapeutic use
MH  - Female
MH  - Health Care Surveys
MH  - Hospitals/statistics & numerical data
MH  - Humans
MH  - Inappropriate Prescribing/*statistics & numerical data
MH  - Lansoprazole/administration & dosage/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Pantoprazole/administration & dosage/therapeutic use
MH  - Proton Pump Inhibitors/administration & dosage/*therapeutic use
MH  - Rabeprazole/administration & dosage/therapeutic use
MH  - Young Adult
EDAT- 2019/08/03 06:00
MHDA- 2020/09/15 06:00
CRDT- 2019/08/03 06:00
PHST- 2019/08/03 06:00 [pubmed]
PHST- 2020/09/15 06:00 [medline]
PHST- 2019/08/03 06:00 [entrez]
AID - 10.17235/reed.2019.6155/2019 [doi]
PST - ppublish
SO  - Rev Esp Enferm Dig. 2019 Oct;111(10):738-743. doi: 10.17235/reed.2019.6155/2019.